Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817343 · ClinicalTrials.gov registry record · Phase 1
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
A Phase 1 study, sponsored by Exegenesis Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT06817343 is a Phase 1 study that is active but no longer recruiting, run by Exegenesis Bio. The registered enrollment target is 12 participants.
The verdict
NCT06817343, a Phase 1 study, is active but no longer recruiting, sponsored by Exegenesis Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD. This study is designed to fulfill the long-term safety monitoring of EXG102-031. Participants that enroll in this long-term follow-up study have been treated with EXG102-031 under the main study (EXG102-031-211).
Interventions
- BIOLOGICAL Aflibercept (2.0 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06817343
The ClinicalTrials.gov registry entry for NCT06817343 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exegenesis Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aflibercept (2.0 mg) is the first listed.
NCT06817343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06817343 about?
NCT06817343 is a clinical study titled "A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)". In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. E...
What is the current status of trial NCT06817343?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-09-10. Estimated completion is 2029-02.
What interventions are being tested in trial NCT06817343?
The interventions under investigation include: Aflibercept (2.0 mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06817343?
This trial is sponsored by Exegenesis Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.